Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
OBJECTIVE
To investigate the mechanism underlying the entry of the analgesic peptide dalargin into brain using biodegradable polybutylcyanoacrylate (PBCA) nanoparticles (NP) overcoated with polysorbate 80.


METHODS
The investigations were carried out with PBCA NP and with non biodegradable polystyrene (PS) NP (200 nm diameter). Dalargin adsorption was assessed by HPLC. Its entry into the CNS in mice was evaluated using the tail-flick procedure. Locomotor activity measurements were performed to compare NP toxicities. BBB permeabilization by PBCA NP was studied in vitro using a coculture of bovine brain capillary endothelial cells and rat astrocytes.


RESULTS
Dalargin loading was 11.7 microg/mg on PBCA NP and 16.5 microg/ mg on PS NP. Adding polysorbate 80 to NP led to a complete desorption. Nevertheless, dalargin associated with PBCA NP and polysorbate 80 induced a potent and prolonged analgesia, which could not be obtained using PS NP in place of PBCA NP. Locomotor activity dramatically decreased in mice dosed with PBCA NP, but not with PS NP. PBCA NP also caused occasional mortality. In vitro, PBCA NP (10 microg/ml) induced a permeabilization of the BBB model.


CONCLUSIONS
A non specific permeabilization of the BBB, probably related to the toxicity of the carrier, may account for the CNS penetration of dalargin associated with PBCA NP and polysorbate 80.
Olivier
J C
JC
Laboratoire de Pharmacie Galénique et Biopharmacie UPRES EA 1223 34, Poitiers, France. jc.olivier@campus.univ-poitiers.fr
Fenart
L
L
Chauvet
R
R
Pariat
C
C
Cecchelli
R
R
Couet
W
W
D000700:Analgesics / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D004659:Enbucrilate / Q000008:administration & dosage / Q000633:toxicity*; D004727:Endothelium / Q000166:cytology / Q000378:metabolism; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000633:toxicity; D005079:Excipients / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D051379:Mice; D008863:Microspheres; D009043:Motor Activity / Q000187:drug effects; D010147:Pain Measurement / Q000187:drug effects; D011136:Polysorbates / Q000008:administration & dosage / Q000633:toxicity*
D000700:Analgesics; D005079:Excipients; D011136:Polysorbates; D016308:Enkephalin, Leucine-2-Alanine; D004659:Enbucrilate; C040996:enkephalin-Leu, Ala(2)-Arg(6)-